Friday, 15 Feb 2019

You are here

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Studies have shown that the risk of major cardiovascular events (MACE) is elevated and not significantly different between RA and AxSpa or PsA (

A total of 4140 consecutive patients from the Australian Rheumatology Association Database with RA, PsA and AS, were followed between September 2001 to January 2015 and were included in the study.

An analysis of 19,627 patient-years showed that (after multivariate adjustment) the CVE risk was lower with TNFI (HR 0.85, 95% CI 0.76–0.95) and other biologic therapies (HR 0.81, 95% CI 0.70–0.95), but not in those who had stopped their biologic agents (HR 0.96, 95% CI 0.83–1.11). CVE risk was the same between RA, PsA and AS patients. 

These studies are similar to other showing the protective CV benefits of sustained therapy with either methotrexate or TNFi. 

This is important as a recent claims database study of 10,254 patients with RA, PsA, or Psoriasis seen between 2006-2015 showed that after initial CV event 15.3% discontinued and 15.5% switched DMARD therapy after index CV event. Independent predictors of DMARD discontinuation included PsO diagnosis, renal disease, hypertension, heart failure, diabetes mellitus, older age, and baseline csDMARD or non-TNFi bDMARD use (vs TNFi bDMARDs).  (

In their study, having RA and heart failure at baseline, but not DMARD use after index event, were independently associated with increased risk of a subsequent CV event.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.

Update on Pregnancy Management in RA

Two recent reports offer good news to rheumatoid arthritis (RA) women who are planning to become pregnant. 

The first studies, RA women experiencing fertility issues who turn to assisted reproductive technology (ART) shows that live births were significantly lower in women with rheumatoid arthritis receiving ART treatment compared to usual rates in women without rheumatoid arthritis.

Multidisciplinary Recommendations for Rheumatoid Foot Problems

Approximately 90% of patients with rheumatoid arthritis (RA) have foot problems. A multidisciplinary panel (including 2 patients, 22 professionals (rheumatologists, rehabilitation physicians, orthopaedic surgeons, specialized nurses, podiatrists, orthopaedic shoe technicians, pedicurists, researchers) in the Netherlands set out to develop recommendations for those who treat RA foot problems. 

Does Seropositivity Change with Therapy?

A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression. Thus while autoantibody levels may be modifiable by our best therapies, modifying CCP or RF levels appears to have limited clinical relevance.